Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR84 | Q9NQS5 | 7/20 | 0.57 |
| ▸ | FFAR1 | O14842 | 2/20 | 0.57 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28150774 | 0.91 | GPR84 (0.55) | GPR84FFAR1FFAR4 | |
| SCHEMBL11274513 | 0.86 | GPR84 (0.63) | GPR84FFAR1FFAR4 | |
| SCHEMBL1148737 | 0.86 | GPR84 (0.63) | GPR84FFAR1FFAR4 | |
| SCHEMBL7768831 | 0.86 | GPR84 (0.63) | GPR84FFAR1FFAR4 | |
| SCHEMBL1295497 | 0.86 | GPR84 (0.63) | GPR84FFAR1FFAR4 | |
| SCHEMBL10490506 | 0.86 | GPR84 (0.63) | GPR84FFAR1FFAR4 | |
| SCHEMBL1296317 | 0.86 | GPR84 (0.63) | GPR84FFAR1FFAR4 | |
| SCHEMBL11750658 | 0.86 | GPR84 (0.63) | GPR84FFAR1FFAR4 | |
| SCHEMBL11271581 | 0.86 | GPR84 (0.63) | GPR84FFAR1FFAR4 | |
| SCHEMBL3424708 | 0.86 | GPR84 (0.63) | GPR84FFAR1FFAR4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130252312-A1 | BIOFUEL PRODUCTION | BIO ARCHITECTURE LAB, INC. (US) | 2013-09-26 | — | — | US | disclosed |
| US-8318473-B2 | Biofuel production | BIO ARCHITECTURE LAB, INC. (US) | 2012-11-27 | — | — | US | disclosed |
| US-8318464-B2 | Biofuel production | BIO ARCHITECTURE LAB, INC. (US) | 2012-11-27 | — | — | US | disclosed |
| US-8211689-B2 | Biofuel production | BIO ARCHITECTURE LAB, INC. (US) | 2012-07-03 | — | — | US | disclosed |
| US-8198056-B2 | Biofuel production | BIO ARCHITECTURE LAB, INC. (US) | 2012-06-12 | — | — | US | disclosed |
| US-20110269215-A1 | BIOFUEL PRODUCTION | BIO ARCHITECTURE LAB, INC. (US) | 2011-11-03 | — | — | US | disclosed |
| US-20110256595-A1 | BIOFUEL PRODUCTION | BIO ARCHITECTURE LAB, INC. (US) | 2011-10-20 | — | — | US | disclosed |
| US-20110244553-A1 | BIOFUEL PRODUCTION | BIO ARCHITECTURE LAB, INC. (US) | 2011-10-06 | — | — | US | disclosed |
| US-20110236939-A1 | BIOFUEL PRODUCTION | BIO ARCHITECTURE LAB, INC. (US) | 2011-09-29 | — | — | US | disclosed |
| US-20110236938-A1 | BIOFUEL PRODUCTION | BIO ARCHITECTURE LAB, INC. (US) | 2011-09-29 | — | — | US | disclosed |
| EP-2195440-A2 | BIOFUEL PRODUCTION | Bio Architecture Lab, Inc. (US) | 2010-06-16 | — | — | EP | disclosed |
| US-20090155873-A1 | BIOFUEL PRODUCTION | BIO ARCHITECTURE LAB, INC. (US) | 2009-06-18 | — | — | US | disclosed |
| US-20090139134-A1 | BIOFUEL PRODUCTION | BIO ARCHITECTURE LAB, INC. (US) | 2009-06-04 | — | — | US | disclosed |
| WO-2009046370-A2 | BIOFUEL PRODUCTION | BIO ARCHITECTURE LAB, INC. (US) | 2009-04-09 | — | — | WO | disclosed |
| WO-2009046375-A2 | BIOFUEL PRODUCTION | BIO ARCHITECTURE LAB, INC. (US) | 2009-04-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090139134-A1 | BIOFUEL PRODUCTION | MGAM, DCXR, MANBA | GPR84 1029/4885FFAR1 1107/4885FFAR4 1011/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.